Evidence map›Paper›PMID 22445478›Full record

ReviewClinical nephrology2012

Diabetic nephropathy among Mexican Americans.

Subrata Debnath, Farook Thameem, Tahira Alves, Jacqueline Nolen, Hania Al-Shahrouri, Shweta Bansal, Hanna E Abboud, Paolo Fanti

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01265563 (Correction of Glutathione Deficiency for Treatment of Diabetic Nephropathy), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01265563 phase2completednot on this map

Correction of Glutathione Deficiency for Treatment of Diabetic Nephropathy

TypeinterventionalSponsorVA Office of Research and DevelopmentRan2011 to 2016Enrolled108ConditionsDiabetic Nephropathy, Proteinuria, Oxidative StressArmsN-acetylcysteine placebo and silibin placebo, N-acetylcysteine active and silibin placebo, N-acetylcysteine placebo and silibin active, N-acetylcysteine active and silibin active, N-acetylcysteine active + high-dose silibin active
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Subrata DebnathDivision of Nephrology, University of Texas Health Science Center, San Antonio, TX, USA.
Farook Thameem
Tahira Alves
Jacqueline Nolen
Hania Al-Shahrouri
Shweta Bansal
Hanna E Abboud
Paolo Fanti
The University of Texas Health Science Center at San Antonio · USAudie L. Murphy Memorial VA Hospital · USMetabolism and Renal Physiology · FR

Funding

Renal Cell Response in DiabetesR01DK078971 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ABBOUD, HANNA E · 2008 to 2012
$1.2M
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic NephropathyR21AT004490 · NCCIH · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FANTI, PAOLO · 2009 to 2011
$499k
NCCIH NIH HHS AT004490NIDDK NIH HHS DK-R01-078971NIDDK NIH HHS R01 DK078971
6 · The paper itself

Abstract

The incidence of diabetic nephropathy (DN) is growing rapidly worldwide as a consequence of the rising prevalence of Type 2 diabetes mellitus (T2DM). Among U.S. ethnic groups, Mexican Americans have a disproportionately high incidence and prevalence of DN and associated end-stage renal disease (ESRD). In communities bordering Mexico, as many as 90% of Mexican American patients with ESRD also suffer from T2DM compared to only 50% of non-Hispanic Whites (NHW). Both socio-economic factors and genetic predisposition appear to have a strong influence on this association. In addition, certain pathogenetic and clinical features of T2DM and DN are different in Mexican Americans compared to NHW, raising questions as to whether the diagnostic and treatment strategies that are standard practice in the NHW patient population may not be applicable in Mexican Americans. This article reviews the epidemiology of DN in Mexican Americans, describes the pathophysiology and associated risk factors, and identifies gaps in our knowledge and understanding that needs to be addressed by future investigations.

Indexed as

Body Mass IndexDiabetes Mellitus, Type 2Diabetic NephropathiesHumansIncidenceKidney Failure, ChronicMexican AmericansObesityPovertyPrevalenceRisk FactorsTexasWhite People

Identifiers

PMID22445478
PMCPMC4407344
OpenAlexW2019818185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.